Status:
COMPLETED
An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
Up to 99 years
Brief Summary
This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions when initiating or switching to insulin therapy with NovoMix® 30 i...
Eligibility Criteria
Inclusion
- Patients with Type 2 diabetes
- Insulin-naive or previously treated by basal only insulin therapy
Exclusion
- Patients who are unlikely to comply with the protocol
- Pregnancy or breastfeeding or intention of becoming pregnant
Key Trial Info
Start Date :
January 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
509 Patients enrolled
Trial Details
Trial ID
NCT00696995
Start Date
January 1 2007
End Date
September 1 2008
Last Update
January 9 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Lahti, Finland, 15110